CA
NZ
UK
AU
IND
US
The USD 184.8 million non-cash goodwillImpairmentstemmed from fair values of the Respiratory Health and Wellness at Home reporting units falling below carrying values. Adjusted EBITDA was USD 141.9 million against USD 146.1 million, a 2.9% decline, and the adjusted margin was 19.0% against 21.7%. …
Net product sales rose to USD 417.3 million from USD 317.4 million. LUMRYZ, added with the Avadel acquisition that closed on February 12, 2026, contributed USD 89.9 million. VIVITROL rose to USD 127.6 million from USD 121.1 million, ARISTADA and ARISTADA INITIO rose to …
Organic sales rose 10% and acquisitions added 7%. International sales were USD 1.06 billion, or 47.8% of the total, led byDemandin Asia. Orders of USD 2.65 billion rose 34.7%, split between a 17% organic increase and an 18% contribution from acquisitions.
The swing to a GAAP loss reflected non-recurringAcquisitionand integration costs of USD 22.3 million tied to the Kashiv acquisition, a higher tax provision and a larger share count. Adjusted EBITDA reached USD 207 million, up 30%.
Net interest income was USD 10.2 million against USD 10.18 million a year earlier. The swing to a GAAP loss came from net unrealized losses of USD 22.6 million on mortgage loans,Fair Valueoption debt,Derivativesand trading securities, compared with a USD 11.3 million gain a …
Fee related earnings rose 23% to a record USD 802 million, helped by management fees of USD 1.017 billion, up 18%, andCapitalsolutions fees of USD 290 million, up 37% and a fourth consecutive quarterly record. Spread related earnings were USD 844 million against USD …
Engineered Components net sales rose 7% to USD 1.835 billion, and its adjusted EBITDA rose 2% to USD 387 million. Intelligent Systems net sales fell 3% to USD 1.402 billion, and its adjusted EBITDA dropped 18% to USD 180 million from USD 219 million. …
The prior year revenue figure included USD 20.6 million under the original vepdegestrant collaboration with Pfizer and a USD 20.0 million development milestone tied to the Novartis license. The Pfizer revenue did not recur after all remaining deferred revenue was recognized in the second …
The GAAP result reflects a USD 475 million noncash settlement charge recognized when the company completed a pension buy-out of its U.K. defined benefit plan. Net sales rose USD 809 million, with USD 648 million from price and mix, mainly higher aluminum prices, and …
Research and development expense was nearly flat at USD 110.1 million versus USD 109.8 million, but the composition shifted. OtherResearch and Developmentcosts rose USD 15.9 million to USD 16.6 million on milestone activity, employee related costs rose USD 4.6 million as research headcount grew …
Please wait processing your request...